DAP3 binding cell death enhancer 1Genealiases: DELE · DELE1(L) · KIAA0141
Q-omics provides the consensus-scored DELE1 profile across patient tissues and cancer cell-line models. DELE1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DELE1 is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, DELE1 RNA expression shows 19,947 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUSC, and THYM as cancer lineages where DELE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DELE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DELE1 survival associations across molecular data types. DELE1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DELE1 RNA expression–survival associations across cancer types. High DELE1 expression shows unfavorable associations in KICH, LUSC and CESC, but favorable associations in KIRC, READ and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DELE1 RNA expression.
This table summarizes DELE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DELE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DELE1 shows lower tumor expression in LUSC, UCEC, LUAD, BLCA and KICH and higher tumor expression in LIHC. The LUSC box plot shows higher DELE1 RNA expression in normal versus tumor tissue (log2 FC = −1.172, t-test p < 0.001).
This table shows molecular features associated with DELE1 in patient tissues and cancer cell lines. In patient samples, DELE1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DELE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
